Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
about
The pancreas cancer microenvironmentThe tumor microenvironment and strategies to improve drug distributionRole of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cellsThe hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.Targeting hypoxia in the leukemia microenvironmentPyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrugAnticancer activity of metal complexes: involvement of redox processes.Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas.Using predrugs to optimize drug candidates.Self-immolative spacers: kinetic aspects, structure-property relationships, and applications.Defining the biological basis of radiomic phenotypes in lung cancer.Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact.Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells.Hypoxia: A Double-Edged Sword in Cancer Therapy.Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds.Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface.Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.2-Nitroimidazole based fluorescent probes for nitroreductase; monitoring reductive stress in cellulo.Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery.Bioreductive fluorescent imaging agents: applications to tumour hypoxia.Hypoxia-activated prodrugs and redox-responsive nanocarriers
P2860
Q27026705-74BA63D2-8522-4904-B244-3503B1062D4EQ28384148-CBF8797A-5204-4913-B53F-2BA94FDC0B7EQ34253642-1688131C-7DF8-42C1-B4FA-79BA08770FABQ34285178-3D1A36D1-1D83-4C5D-83B4-029DB918316CQ34401785-C7153375-462F-4D65-B45B-9E90A2A686ADQ34460489-406C14E5-CD54-4051-90E4-B3D564F884E4Q35005290-1947B696-D166-456B-BA89-07859E8D6A34Q36109993-FA62801B-2593-40CE-82CB-88C6E9FEBFC7Q37415654-45A1F5BA-5213-4FF4-9A69-F736B346A8E1Q37565506-602BDE6A-DBBC-4BF3-A708-0F48FD173E04Q37833099-1273EA14-1CB5-4770-BF2C-DFB5968296ADQ37845832-913E9DFE-6759-479E-AD57-F9C68A4C84DBQ38161730-0C6A77CA-E79B-447B-BE7D-307754D4BBB9Q38243993-7E80EF02-55C2-45B0-8061-551D4E93E783Q38520280-58AE4764-556C-4A4E-B06B-FCC92A46396EQ38668238-340D9300-28E9-49B5-B8AA-72BE8E624A89Q38672565-0530BA4E-8B63-473B-89EF-A70FC1FE24C0Q38682486-BBE63D62-24C0-4232-B1E7-C5D1DE979967Q38824983-0B92DB5D-09F2-46B1-AA48-A269F3BA3581Q38827618-5070AAC5-2B9A-4FAA-81B2-F4EFCA13237CQ39002822-E5A6680F-2116-4313-8B8D-22CD8D790E3FQ39424293-8320302D-00B9-4308-94E5-333EB413B147Q39556460-13BB9876-AE46-4B64-8EF5-F4EC452A13C6Q41467964-70F31933-B7C3-49E2-AC7D-87442DE33E96Q48114384-568F0860-5B1E-47A3-893C-58B42DC2AA64Q48115761-C13E52A3-90B5-4433-B40F-9AF844107D87Q50803523-957AB925-99E5-44C8-BB53-A7A45622FE18Q51543594-AC72F772-AFD6-4848-8919-71994F8161D4Q58694676-BF8DB1DA-D8C2-466C-A549-D7D7922874C0
P2860
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@en
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@nl
type
label
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@en
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@nl
prefLabel
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@en
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@nl
P2860
P356
P1433
P1476
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
@en
P2093
William A Denny
P2860
P304
P356
10.2217/FON.10.1
P407
P577
2010-03-01T00:00:00Z